TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Meilleur Technologies Inc. Has Finalized a Manufacturing Agreement With Pharmalogic for the Production of NAV4694, the Next-generation Amyloid Pet Imaging Biomarker

Thursday, December 21, 2023

Meilleur Technologies Inc. (MTI) has announced a new agreement with PharmaLogic Holdings Corporation ("PharmaLogic"). The agreement grants PharmaLogic exclusive rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess amyloid plaque status in the brain, a hallmark of neurodegenerative diseases such as Alzheimer's Disease (AD).

As per the terms of the agreement, PharmaLogic will produce [F18]NAV4694 for use in clinical trials at selected radiopharmacies in the United States.

Rick Hiatt, President and CEO of Meilleur Technologies, expressed enthusiasm about the collaboration, stating, "We are pleased that PharmaLogic's extensive PET manufacturing and dispensing expertise will support the NAV-694 clinical and research program. Meilleur is committed to advancing technologies to combat neurodegenerative diseases, and we believe NAV4694's unique properties will be valuable in developing therapeutic agents. We are excited to add PharmaLogic to our network of partners, aiming to expand the availability of this investigational imaging agent within the scientific community."

Steve Chilinski, CEO of PharmaLogic, also expressed satisfaction with the partnership, saying, "PharmaLogic is pleased to collaborate with Meilleur Technologies, furthering our commitment to combating challenging diseases, including Alzheimer's Disease."

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit